Drugs / NS2359
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00728208 | Jul → Dec 2008 | depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00032916 | Jun 2001 → Dec 2002 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Unknown | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT02798627 | May 2016 → Mar 2020 | cocaine dependence | University of Pennsylvania | Completed | Missed primary |
| Phase 2 | NCT00448058 | Apr 2007 → Dec 2008 | depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00420641 | Dec 2006 → Jun 2008 | major depressive disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT00467428 | Aug 2003 → Sep 2004 | attention deficit-hyperactivity disorder | NeuroSearch A/S | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-08-13 | Saniona | Regulatory Saniona announces that FDA has approved the IND for NS2359 in cocaine addiction saniona.com ↗
Saniona, a leading biotech company within ion-channel research, announces today that the US Food and Drug Administration, FDA, has accepted the University of Pennsylvania Treatment Research Center's (TRC) Investigational New Drug Application (IND) for NS2359. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-12-16 | Saniona | Saniona's partner TRC will initiate a Phase 2 study for NS2359 in cocaine addiction following grant from Dana Foundation saniona.com ↗ |
| 2015-08-13 | Saniona | Saniona announces that FDA has approved the IND for NS2359 in cocaine addiction saniona.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NS2359 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00032916 ↗ |
| Known as | GSK372475 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00448058 ↗ |
| Action | Inhibit | “inhibits the reuptake of dopamine, norepinephrine and serotonin” NCT02798627 ↗ |
| Modality | Small molecule | “NS2359 is a small molecule” NCT02798627 ↗ |
| Route | Oral | “oral NS2359” NCT00032916 ↗ |